The serotonin 5-HT1A receptor agonist tandospirone improves executive function in common marmosets

Behavioural Brain Research

Volumn 287, Issue , 2015, Pages 120-126

  Baba, Satoko ^a   Murai, Takeshi ^a   Nakako, Tomokazu ^a   Enomoto, Takeshi ^a   Ono, Michiko ^a   Shimizu, Isao ^a   Ikeda, Kazuhito ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Antipsychotic; Common marmoset; Executive function; Object retrieval with detour; Schizophrenia; Serotonin 5 HT1A receptor

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; BLONANSERIN; DOPAMINE 1 RECEPTOR STIMULATING AGENT; HALOPERIDOL; RISPERIDONE; SEROTONIN 1A AGONIST; TANDOSPIRONE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ISOINDOLE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PSYCHOTROPIC AGENT; PYRIMIDINE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN 1A RECEPTOR;

ADJUVANT THERAPY; ADULT; ANIMAL EXPERIMENT; ARTICLE; CALLITHRIX; CONTROLLED STUDY; DRUG EFFICACY; EXECUTIVE FUNCTION; EXPERIMENTAL COGNITIVE TEST; FEMALE; MALE; NONHUMAN; OBJECT RETRIEVAL WITH DETOUR TEST; PRIORITY JOURNAL; TASK PERFORMANCE; AGONISTS; ANIMAL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PSYCHOLOGIC TEST;

ANIMALS; ANTIPSYCHOTIC AGENTS; CALLITHRIX; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EXECUTIVE FUNCTION; HALOPERIDOL; ISOINDOLES; MALE; PIPERAZINES; PIPERIDINES; PSYCHOLOGICAL TESTS; PSYCHOTROPIC DRUGS; PYRIMIDINES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D1; RISPERIDONE; SEROTONIN 5-HT1 RECEPTOR AGONISTS;

EID: 84926349228     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.03.025     Document Type: Article

References (25)

1. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the right stuff. Schizophr Bull 2000, 26:119-136.
2. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005, 8:457-472.
3. Miyamoto S., Miyake N., Jarskog L.F., Fleischhacker W.W., Lieberman J.A. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 2012, 17:1206-1227.
4. Meltzer H.Y., Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia. Behav Brain Res 2008, 195:98-102.
5. Meltzer H.Y. Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb Exp Pharmacol 2012, 212:87-124.
6. Sumiyoshi T., Higuchi Y. Facilitative effect of serotonin(1A) receptor agonists on cognition in patients with schizophrenia. Curr Med Chem 2013, 20:357-362.
7. Yabuuchi K., Tagashira R., Ohno Y. Effects of tandospirone, a novel anxiolytic agent, on human 5-HT1A receptors expressed in Chinese hamster ovary cells (CHO cels). Biog Amines 2004, 18:319-328.
8. Sumiyoshi T., Matsui M., Yamashita I., Nohara S., Kurachi M., Uehara T., et al. The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 2001, 49:861-868.
9. Sumiyoshi T., Matsui M., Nohara S., Yamashita I., Kurachi M., Sumiyoshi C., et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 2001, 158:1722-1725.
10. Horiguchi M., Meltzer H.Y. The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology (Berl) 2012, 221:205-215.
11. Buchanan R.W., Davis M., Goff D., Green M.F., Keefe R.S., Leon A.C., et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005, 31:5-19.
12. Enomoto T., Ishibashi T., Tokuda K., Ishiyama T., Toma S., Ito A. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 2008, 186:197-207.
13. Ishiyama T., Tokuda K., Ishibashi T., Ito A., Toma S., Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007, 572:160-170.
14. Murai T., Nakako T., Ikejiri M., Ishiyama T., Taiji M., Ikeda K. Effects of lurasidone on executive function in common marmosets. Behav Brain Res 2013, 246:125-131.
15. Murai T., Nakako T., Ikeda K., Ikejiri M., Ishiyama T., Taiji M. Lack of dopamine D4 receptor affinity contributes to the procognitive effect of lurasidone. Behav Brain Res 2014, 261:26-30.
16. Wallis J.D., Dias R., Robbins T.W., Roberts A.C. Dissociable contributions of the orbitofrontal and lateral prefrontal cortex of the marmoset to performance on a detour reaching task. Eur J Neurosci 2001, 13:1797-1808.
17. Wilkinson L.S., Dias R., Thomas K.L., Augood S.J., Everitt B.J., Robbins T.W., et al. Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioural response to D-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys. Neuroscience 1997, 80:717-730.
18. Nakako T., Murai T., Ikejiri M., Ishiyama T., Taiji M., Ikeda K. Effects of a dopamine D1 agonist on ketamine-induced spatial working memory dysfunction in common marmosets. Behav Brain Res 2013, 249:109-115.
19. Rutten K., Basile J.L., Prickaerts J., Blokland A., Vivian J.A. Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology (Berl) 2008, 196:643-648.
20. Baba S., Enomoto T., Horisawa T., Hashimoto T., Ono M. Blonanserin extensively occupies rat dopamine D3 receoits at antipsychotic dose range. J Pharmacol Sci 2015, 10.1016/j.jphs.01.007.
21. Murasaki M., Nishikawa H., Ishibashi T. Dopamine-serotonin antagonist: Receptor biding profile of a novel antipsychotic blonanserin. Jpn J Clin Psychopharmacol 2008, 11:845-854. Japanese.
22. Horiguchi M., Meltzer H.Y. Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: role of indirect 5-HT(1A) partial agonism. Behav Brain Res 2013, 247:158-164.
23. Huang M., Panos J.J., Kwon S., Oyamada Y., Rajagopal L., Meltzer H.Y. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin 5-HT2A and DA D2 antagonism and 5-HT1A partial agonism. J Neurochem 2014, 128:938-949.
24. Yoshino T., Nisijima K., Katoh S., Yui K., Nakamura M. Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex. Neurochem Int 2002, 40:355-360.
25. Goldman-Rakic P.S., Castner S.A., Svensson T.H., Siever L.J., Williams G.V. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004, 174:3-16.